The alkaline phosphatases [orthophosphoric-monoester phosphohydrolase (alkaline optimum), EC 3.1.3.1] are a group of metalloenzymes that hydrolyze phosphate esters at a high pH optimum (pH 10-10.5) . At least three gene loci exist for the human alkaline phosphatases (ALPases) including term placental ALPase (pALPase), intestinal ALPase (iALPase), and liver/kidney/bone, or tissue unspecific, ALPase (lkbALPase). The enzymes are dimers-the subunits are of 64,000-72,000 in Mr and are structurally, biochemically, and immunologically distinct.
pALPase is of particular interest from both a genetic and medical standpoint because of its extensive genetic polymorphism and ectopic expression in some human cancers. The first suggestion that pALPase might be useful as a tumor marker came in 1968 when Fishman et al. (1) reported the production of a placental-like ALPase by a bronchogenic carcinoma. Subsequent studies have revealed the ectopic production of the placental isoenzyme of ALPase in a variety of malignancies (2) , with a particularly high prevalence in germ cell tumors, such as seminomas (3, 4) and ovarian and uterine cancer (3, 5, 6) .
The polymorphic nature of pALPase was first documented by Boyer in 1961 (7) , and subsequent electrophoretic, immunologic, and genetic studies in human populations suggest there are three common alleles of the pALPase gene (8) (9) (10) . These common types were designated pALPase', pALPase2, and pALPase3, which were suggested to give rise to six common phenotypes defined by homozygotes 1:1, 2:2, and 3:3 and heterozygotes 1:2, 1:3, and 2:3. In addition, many rare alleles are responsible for a large number of electrophoretically and immunologically detectable enzyme variants (accounting for 2.5% ofthe population) that are believed to be heterozygotes of one of the three common alleles and one of these rare alleles (8) (9) (10) (11) (12) .
In this study we use a full-length pALPase cDNA probe to provide evidence of allelic Pst I restriction fragment length polymorphism of the pALPase gene locus. We also compare the genomic DNA of normal placentae and several germ cell tumors by Southern blot analysis.
MATERIALS AND METHODS
Tissue Samples. Biopsies of tumor tissue and normal ovaries used for DNA isolation were immediately frozen in liquid nitrogen. Normal term placentae were obtained within 30 min of delivery, and samples of villus tissue totaling -15 g of wet weight were excised and frozen in liquid nitrogen.
Cell Lines. The human choriocarcinoma cell line BeWo was obtained from the American Type Culture Collection (ATCC CCL98) and was grown in 50% Waymouth's MB 752/1 medium, 40% Gey's balanced salt solution, and 10% fetal calf serum with antibiotics.
Peripheral Blood Nonactivated Lymphocytes. Twenty milliliters ofperipheral blood was collected in heparinized tubes.
Isolation of DNA from Tissue. Frozen pieces of tissue were crushed to powder in liquid nitrogen and lysed with 10 vol of a solution of 0.5 M EDTA, pH 8.0/0.5% (wt/vol) Nlauroylsarcosine (Sigma) containing 100 ,4g of proteinase K per ml (Sigma). Lysates were incubated overnight at 50'C. Protein was removed with three phenol extractions, and the remaining solution was extensively dialyzed in 50 mM 2-amino-2-hydroxymethyl-1,3-propanediol (Tris), pH 8 Probe. The probe used in this study was a cloned 2.7-kb pALPase cDNA prepared as described (13) . The Starch Gel Electrophoresis. Placental samples were extracted with 1-butyl alcohol, and aliquots taken from the aqueous phase were electrophoresed in starch gels as described (16) . ALPase was visualized by gently shaking the gels at room temperature in 100 ml of 0.06 M borate buffer (pH 9.7) containing 50 mg of 8-naphthyl phosphate, 120 mg of MgSO4'7H2O, and 50 mg of fast blue B (o-dianisidine) salt.
After development, the gels were fixed in a 50% 'methanol/ 10% acetic acid solution.
Solid-Phase Immunoenzyme Assay. The solid-phase immunoenzyme assay was described by McLaughlin et al. (17) . The monoclonal antibodies used in the study were AAP1, which is specific for the fetal and adult forms of iATPase; (Fig. 3) , indicating that no major gene rearrangement is necessary for the re-expression of pALPase in neoplasia.
The gene frequencies for the Pst I-and Pst I' alleles were computed from the genotype ratios presented in Table 1 Pst I--genotype is present in 64% of the individuals tested, Pst I`is present in 33%, and Pst I" is present in 3%. When these numbers were used to solve the binomial expression, gene frequencies were found to be 0.80 and 0.21 for Pst I -and Pst I+, respectively.
The allelic pALPase phenotypes of the placentae were isotyped by starch gel electrophoresis to determine whether a correlation exists between any of the alleles and the Pst I restriction patterns. The results presented in Table 2 show no direct correlation between allelic phenotype and genomic restriction fragment length polymorphism.
DISCUSSION
The data presented here provide evidence of a Pst I restriction fragment length polymorphism of the human pALPase gene locus. Pst I digestion of total genomic DNA from placentae results in a reproducible pattern consisting ofeither five or six bands upon hybridization with a full-length 2.7-kb cDNA probe.
To date, the nucleotide sequences of four different pALPase cDNA molecules have been published (13, 18, 19 are all quite similar but exhibit nucleotide substitutions at several positions that in some cases lead to amino acid changes at the corresponding positions. Unaffected by these substitutions are the three Pst I restriction endonuclease sites that are present at the corresponding regions on all four clones. Therefore, based on the restriction map of the cDNA clone, four restriction fragments would be expected from Pst I digestion. The extra band seen in the blots is the result of an additional Pst I recognition site located in the noncoding flanking or intronic regions of genomic DNA.
The extra band at 1.1 kb appears to be the result of genetic polymorphism. In several independent experiments the band was clearly and reproducibly absent or present in one or two copies as judged by the autoradiographic density of the band. The allele(s) lacking the 1.1-kb Pst I fragment (Pst I-) represent the most abundant species, with the homozygote Pst I--making up 64% of the samples tested. The heterozygote Pst I' -occurred in 33% of the samples, whereas Pst I" samples accounted for only 3% of the population.
The polymorphism is probably due to a point mutation leading to the creation or destruction of the extra Pst I site. This view is consistent with the results of studies on the P-globin locus that have shown that at least 1 in 100 base pairs varies polymorphically (20) . A comparison of the restriction fragment patterns and starch gel electrophoresis-defined phenotype for each placenta (Table 2 ) reveals no direct relationship between restriction fragment pattern and any phenotype. This lack of correlation indicates that the restriction fragment length polymorphism is in one of the Pst I sites located in the noncoding regions of the pALPase gene. There does, however, appear to be a higher likelihood of those placentae expressing type 1 pALPase to be Pst I-. The common explanation for the diversity of the ALPases is duplication and mutation of a common ancestral gene.
We believe that by performing hybridization and washing under conditions of high stringency (420C hybridization and three 1-hr washes at 650C) we have reduced the possibility of cross-hybridization with other genes in the ALPase family. The nucleotide sequence of a cDNA clone of the human lkbALPase shows 52% homology to pALPase (21) . Because the melting point of duplex DNA is reduced by 1PC with an increase of 1% in the number of mismatch base pairs (22) , the 48% mismatch between lkbATPase and pALPase should exclude detection of lkbATPase genes with the pALPase cDNA under these conditions. In fact, Kam et al. (13) failed to detect mRNA in human liver with the same pALPase cDNA probe used in the present study. There is a greater likelihood of cross-hybridization between the pALPase probe and the iALPase gene based on the 88% nucleotidesequence homology in the protein-coding regions of iALPase and pALPase cDNA molecules (23) . However, the pALPase probe used in this study has only shown weak hybridization with mRNA from human small intestine under conditions of moderate stringency by RNA blot analysis (24) . In the present study, the bands in the Southern blots used to demonstrate the polymorphism are of high intensity, suggesting that these bands are not the result of weak cross-hybridization with the iALPase gene (Figs. 1-3) . Although the use of high-stringency conditions greatly reduces cross-hybridization, the possibility that restriction fragments from the iALPase gene contribute to the digestion pattern cannot be completely excluded.
It is apparent from the studies done on seminoma and tumors of the ovaries and endometrium that no major genetic rearrangement is occurring involving the pALPase locus in ectopic expression. The eight tumors studied showed the same restriction fragment pattern and relative polymorphic distribution as those of placental tissue; additionally, the DNA restriction pattern of peripheral lymphocytes did not differ from that of the ovarian tumor in a patient. Furthermore, other restriction enzymes-EcoRI, Sma I, BamHI, and Sac I-failed to detect a polymorphism either in normal placenta or tumor tissue. If a genetic transposition of the pALPase gene were required for its ectopic expression in tumor, one would expect to see some difference in the restriction pattern between normal and neoplastic tissue. The lack of global rearrangement suggests an alternative mechanism is responsible for the expression of pALPase isoenzymes in neoplasia.
Note Added in Proof: Southern blot analyses were performed on the same Pst I human genomic DNA digests using an iALPase cDNA probe (generously provided by Dr. Harry Harris, Department of Genetics, University of Pennsylvania). The results show that the intestinal probe hybridizes weakly to the polymorphic 1.1-kb fragment in contrast to the strong hybridization observed with the placental probe, indicating that the polymorphism is derived from the pALPase gene.
This work was supported by Grants CA13533 and CA09151 from the National Institutes of Health. We thank Dr. Nelson Teng (Department of Obstetrics and Gynecology, Stanford University) for generously providing tumor samples and Lucille Weiss for her expert secretarial assistance.
